Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Change in Cash (2016 - 2025)

Historic Change in Cash for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $2.1 million.

  • Utah Medical Products' Change in Cash rose 37222.95% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2 million, marking a year-over-year decrease of 182222.22%. This contributed to the annual value of -$9.9 million for FY2024, which is 15552.31% down from last year.
  • Latest data reveals that Utah Medical Products reported Change in Cash of $2.1 million as of Q3 2025, which was up 37222.95% from -$1.1 million recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Change in Cash ranged from a high of $5.9 million in Q1 2023 and a low of -$5.5 million during Q4 2024
  • For the 5-year period, Utah Medical Products' Change in Cash averaged around $1.7 million, with its median value being $3.3 million (2022).
  • As far as peak fluctuations go, Utah Medical Products' Change in Cash surged by 95612.54% in 2023, and later plummeted by 22379.28% in 2024.
  • Quarter analysis of 5 years shows Utah Medical Products' Change in Cash stood at -$3.3 million in 2021, then skyrocketed by 265.55% to $5.5 million in 2022, then dropped by 15.92% to $4.7 million in 2023, then tumbled by 217.54% to -$5.5 million in 2024, then soared by 138.13% to $2.1 million in 2025.
  • Its Change in Cash stands at $2.1 million for Q3 2025, versus -$1.1 million for Q2 2025 and $349000.0 for Q1 2025.